Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)

We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Regeneron Pharmaceuticals, Inc. is among the most profitable stocks.

TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock. The firm expressed confidence in REGN’s updated outlook and recent pricing actions. Evercore ISI identified Dupixent and Eylea HD as key players in the company’s growth and noted that both products are well-positioned to sustain current competitiveness and improve future performance.

Similarly, earlier this month, on January 8, Goldman Sachs also raised its price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $914 from $807 and gave it a Buy rating. The firm cited strong sector performance in 2025 and expects the positive momentum to continue into 2026, which is supported by favorable market conditions, easing policy risks, and potential M&A activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company specializing in the discovery, development, and commercialization of innovative medicines for serious diseases.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.